Telmisartan/Amlodipine/Chlorthalidone(Truset)
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Jun 8, 2022 → Mar 31, 2027
NCT ID
NCT06282549About Telmisartan/Amlodipine/Chlorthalidone(Truset)
Telmisartan/Amlodipine/Chlorthalidone(Truset) is a pre-clinical stage product being developed by Yuhan for Essential Hypertension. The current trial status is active. This product is registered under clinical trial identifier NCT06282549. Target conditions include Essential Hypertension.
What happened to similar drugs?
15 of 20 similar drugs in Essential Hypertension were approved
Approved (15) Terminated (2) Active (5)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06282549 | Pre-clinical | Active |
Competing Products
20 competing products in Essential Hypertension